Cencora's stock rises as analysts raise price targets, and the company boosts its dividend by 12.67%.

Cencora, a pharmaceutical distribution company, saw its shares rise after several analysts raised their price targets. The company declared a $0.55 quarterly dividend, up 12.67%, and the stock has a "Moderate Buy" consensus rating. Institutional investors, including Versor Investments LP, are actively buying shares. Cencora's CEO sold a significant amount of stock recently, while the company's market cap is $49.05 billion with a P/E ratio of 33.08.

November 11, 2024
4 Articles